Advanced Enzyme Technologies Buyback: Key Details 2026

What the board approved on August 8, 2026

Advanced Enzyme Technologies Limited said its Board of Directors, at a meeting held on August 08, 2026, approved an open-market share buyback alongside the company’s unaudited financial results for the quarter ended June 30, 2026. The buyback proposal caps the repurchase amount at ₹69.70 crore, with a maximum buyback price of ₹500 per equity share. The company also stated the buyback will be executed through the stock exchange mechanism.

The same board meeting also cleared other corporate actions involving subsidiaries, including the acquisition of the remaining minority stake in JC Biotech Private Limited and additional funding for Advanced Nutrazyme Private Limited. The company indicated that a detailed public announcement, including process and timelines, will be released in due course.

Buyback size, price, and percentage of equity

As per the disclosed terms, the aggregate buyback size will not exceed ₹69.70 crore, and the maximum price is ₹500 per share. At the ceiling price and maximum size, the indicative maximum number of shares to be bought back is 1,394,000 equity shares (13,94,000 shares). The company said this represents approximately 1.24% of the existing paid-up equity capital.

The equity shares carry a face value of ₹2 per share. The buyback consideration is to be paid in cash. The stock is listed on both BSE and NSE.

Route and participation: open market via stock exchanges

Advanced Enzyme Technologies said the buyback will be conducted through the “Open Market” route via the stock exchange mechanism. It also specified that shares held by Promoters, the Promoter Group, and persons in control of the company will be excluded from the buyback.

Some buyback trackers describe the mechanism as “through stock exchange” and also use the term “tender offer” in the same context. However, the company’s disclosure explicitly describes the buyback route as open market through the stock exchange mechanism.

Key dates: record date and schedule still awaited

The open and close dates for the Advanced Enzyme Technologies Buyback 2026 were stated as not available at the time of the update. Similarly, the buyback record date and other milestone dates were shown as “2026” without specific dates.

The company has said that a public announcement including the process and timelines will be issued in due course. Until then, investors do not have a confirmed calendar for the record date, opening date, or closing date.

Pricing context: premium versus last close

Market notes around the announcement highlighted that the buyback price of ₹500 per share implies a sizeable premium over the previous closing price cited at ₹324.35. The premium was described as roughly 54%.

This pricing reference matters because open-market buybacks are executed through exchange trades up to the maximum price, subject to regulatory conditions and the company’s execution strategy.

Q1 (quarter ended June 30, 2026) update included in the meeting

Along with the capital return proposal, the board approved unaudited financial results for the quarter ended June 30, 2026, and a Limited Review Report. The update described profit after tax (PAT) at ₹38.6 crore versus ₹40.4 crore, a decline of 4.6%.

The company’s disclosure tied the financial approvals and the buyback decision to the same board meeting date of August 08, 2026.

Other board decisions: JC Biotech buyout and Nutrazyme funding

Beyond the buyback, the board approved acquiring the remaining 4.28% stake in JC Biotech Private Limited (JCB). The disclosed consideration for this acquisition was ₹7.98 crore, which would make JCB a wholly-owned subsidiary.

In addition, the board cleared a further fund infusion of up to ₹2.00 crore into Advanced Nutrazyme Private Limited. These actions were presented as part of a broader set of steps involving subsidiaries.

Regulatory framework cited by the company

Advanced Enzyme Technologies stated that the buyback will be carried out in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013. It reiterated that the execution will happen through the stock exchange mechanism under the open-market route.

The company also signalled that formal communication with full procedural details will follow through a public announcement.

Key facts table

What investors should track next

The biggest pending item is the detailed public announcement that will specify the process and timelines, including the record date and the opening and closing dates. Until those dates are formally announced, eligibility and participation mechanics remain incomplete in the public domain.

Separately, investors tracking the broader board actions may also watch for follow-through on the JC Biotech stake purchase and the additional infusion into Advanced Nutrazyme, both approved alongside the buyback on August 08, 2026.

Company contact details (as provided)

Advanced Enzyme Technologies Ltd., Sun Magnetica, ‘A’ wing, 5th Floor, LIC Service Road, Louiswadi, Thane, Maharashtra 400604. Phone: +91-22-4170 3200. Website: https://www.advancedenzymes.com/.